About

Oak Hill Bio is a clinical-stage biotechnology company focused on acquiring and developing outstanding rare disease drugs that have been deprioritized by big pharma. The company's lead program is rugonersen (OHB-724), an investigational oligonucleotide entering Phase 3 that has best-in-class potential as a treatment for Angelman syndrome, a devastating neurodevelopmental disorder with no approved disease-modifying therapies.
‍
Oak Hill Bio is the trading name for OHB Pediatrics Ltd. It was formed in 2024 as a subsidiary of Oak Hill Bio Holdings (formerly known as Oak Hill Bio Ltd). Oak Hill Bio Holdings is developing OHB-607, a replacement therapy designed to prevent complications of prematurity in extremely preterm infants which is currently in a phase 2b study. For more information about Oak Hill Bio Holdings, please visit www.oakhillbioholdings.com